Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 23
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Moleculin Biotech Inc
MBRX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$5.89
-0.42
-6.66%
Dern. MÀJ: Oct 23, 5:03 AM
$5.76
-0.54
-8.64%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
Privacy Manager
Fractionnement d'actions:
Moleculin Biotech Inc s'est récemment scindé Tuesday, October 20, 2026 avec un ratio de 1:20
Moleculin Biotech Financials
Moleculin Biotech (MBRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of $(12.25) per share
Benzinga Newsdesk
PRO
Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the analyst consensus estimate of $(1.57) by 125.48 percent. This is a 77.59 percent increase over losses of $(15.80) per share
Benzinga Newsdesk
PRO
Moleculin Biotech Q4 EPS $(26.06) Misses $(11.60) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the analyst consensus estimate of $(11.60) by 124.75 percent. This is a 181.73 percent decrease over losses of $(9.25) per
Benzinga Newsdesk
Nasdaq Surges 100 Points; Dollar General Earnings Beat Views
Avi Kapoor
US Stocks Mixed; Nvidia Posts Upbeat Earnings
Avi Kapoor
PRO
Moleculin Biotech Q2 EPS $(0.49) Misses $(0.42) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.42) by 16.67 percent. This is a 71.18 percent increase over losses of $(1.70) per share
Benzinga Newsdesk
